| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 21
| Issue : 1 | Page : 32-36 |
|
|
Anticoagulation in patients with atrial fibrillation and coronary artery disease
Fahad Abdullah Alkindi, Ihsan Mahmoud Rafie
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
Correspondence Address:
Dr. Fahad Abdullah Alkindi
Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha
Qatar
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_138_19
|
|
|
The management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary artery disease remains a challenge in clinical practice. This group of patients has indications for both oral anticoagulation and antiplatelet therapy. Such combination will require careful considerations of both thromboembolic and bleeding risks. There have been several big trials looking at the rationale of treating those patients with an oral anticoagulant in combination with one (dual-therapy strategy) or two antiplatelet agents (triple-therapy strategy).
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
